A thermostable messenger RNA based vaccine against rabies

PLoS Neglected Tropical Diseases

Volumn 11, Issue 12, 2017, Pages

  Stitz, Lothar ^a,c   Vogel, Annette ^a,d   Schnee, Margit ^b   Voss, Daniel ^b,e   Rauch, Susanne ^b   Mutzke, Thorsten ^b   Ketterer, Thomas ^b   Kramps, Thomas ^b,f   Petsch, Benjamin ^b  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b CureVac GmbH   (Germany)

^c BioNTech RNA Pharmaceuticals GmbH ^*  (Germany)

^d BIONTECH AG   (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

^f Novartis Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RABIES VACCINE; GLYCOPROTEIN; GLYCOPROTEIN G, RABIES VIRUS; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL CULTURE; FREEZE DRYING; IMMUNIZATION; IMMUNOGENICITY; LD50; MOUSE; NONHUMAN; THERMOSTABILITY; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; RABIES; RABIES VIRUS; TEMPERATURE; VACCINE IMMUNOGENICITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; GLYCOPROTEINS; IMMUNOGENICITY, VACCINE; MICE; RABIES; RABIES VACCINES; RABIES VIRUS; RNA, MESSENGER; TEMPERATURE; VACCINE POTENCY; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 85039055808     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006108     Document Type: Article

References (19)

1. Kristensen D, Chen D, Cummings R, (2011) Vaccine stabilization: research, commercialization, and potential impact. Vaccine29: 7122–7124. doi: 10.1016/j.vaccine.2011.05.070 21651941
2. Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C, (2007) Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine25: 3980–3986. doi: 10.1016/j.vaccine.2007.02.052 17382434
3. Wirkas T, Toikilik S, Miller N, Morgan C, Clements CJ, (2007) A vaccine cold chain freezing study in PNG highlights technology needs for hot climate countries. Vaccine25: 691–697. doi: 10.1016/j.vaccine.2006.08.028 16968657
4. Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, et al. (2009) Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccin5: 26–32. 18971625
5. Chen D, Kristensen D, (2009) Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines8: 547–557. doi: 10.1586/erv.09.20 19397412
6. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ, (2014) Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv11: 885–899. doi: 10.1517/17425247.2014.901308 24665982
7. Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, et al. (2016) An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl Trop Dis10: e0004746. doi: 10.1371/journal.pntd.0004746 27336830
8. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, et al. (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol30: 1210–1216. doi: 10.1038/nbt.2436 23159882
9. Jones KL, Drane D, Gowans EJ, (2007) Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques43: 675–681. 18072597
10. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, et al. (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother34: 1–15. doi: 10.1097/CJI.0b013e3181f7dbe8 21150709
11. Hoerr I, Obst R, Rammensee HG, Jung G, (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol30: 1–7. doi: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-# 10602021
12. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, et al. (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet.
13. Pascolo S, (2008) Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol: 221–235.
14. Cliquet F, Aubert M, Sagné L, (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. Journal of Immunological Methods212: 79–87. 9671155
15. Saxena S, Sonwane AA, Dahiya SS, Patel CL, Saini M, et al. (2009) Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein. Vet Microbiol136: 36–44. doi: 10.1016/j.vetmic.2008.10.030 19081687
16. Sudarshan MK, Mahendra BJ, Madhusudana SN, Narayana DH, Sanjay TV, et al. (2005) Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Results of a meta-analysis. Hum Vaccin1: 187–190. 17033270
17. Lankester FJ, Wouters PA, Czupryna A, Palmer GH, Mzimbiri I, et al. (2016) Thermotolerance of an inactivated rabies vaccine for dogs. Vaccine34: 5504–5511. doi: 10.1016/j.vaccine.2016.10.015 27729174
18. Smith TG, Siirin M, Wu X, Hanlon CA, Bronshtein V, (2015) Rabies vaccine preserved by vaporization is thermostable and immunogenic. Vaccine33: 2203–2206. doi: 10.1016/j.vaccine.2015.03.025 25812841
19. Montagnon B, Fanget B (1996) Purified Vero cell vaccine for humans, WHO Laboratory techniques in rabies 4th edition, chapter 26. 4.